The NF2 Tumor Suppressor Gene Product, Merlin, Inhibits Cell Proliferation and Cell Cycle Progression by Repressing Cyclin D1 Expression

REFERENCES

• Albanese, C., J. Johnson, G. Watanabe, N. Eklund, D. Vu, A. Arnold, and R. G. Pestell. 1995. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 270:23589–23597.
   PubMed Web of Science ®Google Scholar
• Balasenthil, S., A. A. Sahin, C. J. Barnes, R. A. Wang, R. G. Pestell, R. K. Vadlamudi, and R. Kumar. 2004. p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J. Biol. Chem. 279:1422–1428.
   PubMedGoogle Scholar
• Bar-Sagi, D., and A. Hall. 2000. Ras and Rho GTPases: a family reunion. Cell 103:227–238.
   PubMed Web of Science ®Google Scholar
• Bashour, A. M., J. J. Meng, W. Ip, M. MacCollin, and N. Ratner. 2002. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human schwannoma cells. Mol. Cell. Biol. 22:1150–1157.
   PubMed Web of Science ®Google Scholar
• Bianchi, A. B., S.-I. Mitsunaga, J. Q. Cheng, W. M. Klein, S. C. Jhanwar, B. Seizinger, N. Kley, A. J. P. Klein-Szanto, and J. R. Testa. 1995. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl. Acad. Sci. USA 92:10854–10858.
   PubMed Web of Science ®Google Scholar
• Cheng, J. Q., W. C. Lee, M. A. Klein, G. Z. Cheng, S. C. Jhanwar, and J. R. Testa. 1999. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 24:238–242.
   PubMed Web of Science ®Google Scholar
• Deguen, B., L. Goutebroze, M. Giovannini, C. Boisson, R. van der Neut, M. C. Jaurand, and G. Thomas. 1998. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. Int. J. Cancer 77:554–560.
   PubMedGoogle Scholar
• Eblen, S. T., J. K. Slack, M. J. Weber, and A. D. Catling. 2002. Rac-PAK signaling stimulates extracellular signal-regulated kinase (ERK) activation by regulating formation of MEK1-ERK complexes. Mol. Cell. Biol. 22:6023–6033.
   PubMed Web of Science ®Google Scholar
• Evans, D. G., M. Sainio, and M. E. Baser. 2000. Neurofibromatosis type 2. J. Med. Genet. 37:897–904.
   PubMed Web of Science ®Google Scholar
• Giovannini, M., E. Robanus-Maandag, M. van der Valk, M. Niwa-Kawakita, V. Abramowski, L. Goutebroze, J. M. Woodruff, A. Berns, and G. Thomas. 2000. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 14:1617–1630.
   PubMed Web of Science ®Google Scholar
• He, T. C., S. Zhou, L. T. da Costa, J. Yu, K. W. Kinzler, and B. Vogelstein. 1998. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95:2509–2514.
   PubMed Web of Science ®Google Scholar
• Hirokawa, Y., A. Tikoo, J. Huynh, T. Utermark, C. O. Hanemann, M. Giovannini, G. H. Xiao, J. R. Testa, J. Wood, and H. Maruta. 2004. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J. 10:20–26.
   PubMed Web of Science ®Google Scholar
• Hulit, J., C. Wang, Z. Li, C. Albanese, M. Rao, D. Di Vizio, S. Shah, S. W. Byers, R. Mahmood, L. H. Augenlicht, R. Russell, and R. G. Pestell. 2004. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol. Cell. Biol. 24:7598–7611.
   PubMed Web of Science ®Google Scholar
• Ikeda, K., Y. Saeki, C. Gonzalez-Agosti, V. Ramesh, and E. A. Chiocca. 1999. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. J. Neurosurg. 91:85–92.
   PubMed Web of Science ®Google Scholar
• Joyce, D., B. Bouzahzah, M. Fu, C. Albanese, M. D'Amico, J. Steer, J. U. Klein, R. J. Lee, J. E. Segall, J. K. Westwick, C. J. Der, and R. G. Pestell. 1999. Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-κB-dependent pathway. J. Biol. Chem. 274:25245–25249.
   PubMed Web of Science ®Google Scholar
• Kim, J. Y., H. Kim, S. S. Jeun, S. J. Rha, Y. H. Kim, Y. J. Ko, J. Won, K. H. Lee, H. K. Rha, and Y. P. Wang. 2002. Inhibition of NF-κB activation by merlin. Biochem. Biophys. Res. Commun. 296:1295–1302.
   PubMedGoogle Scholar
• Kissil, J. L., K. C. Johnson, M. S. Eckman, and T. Jacks. 2002. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J. Biol. Chem. 277:10394–10399.
   PubMed Web of Science ®Google Scholar
• Kissil, J. L., E. W. Wilker, K. C. Johnson, M. S. Eckman, M. B. Yaffe, and T. Jacks. 2003. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol. Cell 12:841–849.
   PubMed Web of Science ®Google Scholar
• LaJeunesse, D. R., B. M. McCartney, and R. G. Fehon. 1998. Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localization. J. Cell Biol. 141:1589–1599.
   PubMed Web of Science ®Google Scholar
• Lallemand, D., M. Curto, I. Saotome, M. Giovannini, and A. I. McClatchey. 2003. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 17:1090–1100.
   PubMed Web of Science ®Google Scholar
• Li, W., H. Chong, and K. L. Guan. 2001. Function of the Rho family GTPases in Ras-stimulated Raf activation. J. Biol. Chem. 276:34728–34737.
   PubMedGoogle Scholar
• Lutchman, M., and G. A. Rouleau. 1995. The neurofibromatosis type 2 gene product, schwannomin, suppresses growth of NIH 3T3 cells. Cancer Res. 55:2270–2274.
   PubMedGoogle Scholar
• Matsushime, H., D. E. Quelle, S. A. Shurtleff, M. Shibuya, C. J. Sherr, and J. Y. Kato. 1994. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14:2066–2076.
   PubMed Web of Science ®Google Scholar
• McClatchey, A. I., I. Saotome, K. Mercer, D. Crowley, J. F. Gusella, R. T. Bronson, and T. Jacks. 1998. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 12:1121–1133.
   PubMed Web of Science ®Google Scholar
• Morrison, H., L. S. Sherman, J. Legg, F. Banine, C. Isacke, C. A. Haipek, D. H. Gutmann, H. Ponta, and P. Herrlich. 2001. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 15:968–980.
   PubMed Web of Science ®Google Scholar
• Nheu, T., H. He, Y. Hirokawa, F. Walker, J. Wood, and H. Maruta. 2004. PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition. Cell Cycle 3:71–74.
   PubMedGoogle Scholar
• Pelton, P. D., L. S. Sherman, T. A. Rizvi, M. A. Marchionni, P. Wood, R. A. Friedman, and N. Ratner. 1998. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human schwannoma cells. Oncogene 17:2195–2209.
   PubMed Web of Science ®Google Scholar
• Schulze, K. M., C. O. Hanemann, H. W. Muller, and H. Hanenberg. 2002. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Hum. Mol. Genet. 11:69–76.
   PubMedGoogle Scholar
• Sekido, Y., H. I. Pass, S. Bader, D. J. Y. Mew, M. F. Christman, A. F. Gazdar, and J. D. Minna. 1995. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 55:1227–1231.
   PubMed Web of Science ®Google Scholar
• Shaw, R. J., J. G. Paez, M. Curto, A. Yaktine, W. M. Pruitt, I. Saotome, J. P. O'Bryan, V. Gupta, N. Ratner, C. J. Der, T. Jacks, and A. I. McClatchey. 2001. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev. Cell 1:63–72.
   PubMed Web of Science ®Google Scholar
• Sherman, L., H. M. Xu, R. T. Geist, S. Saporito-Irwin, N. Howells, H. Ponta, P. Herrlich, and D. H. Gutmann. 1997. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15:2505–2509.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J., and J. M. Roberts. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1502.
   PubMed Web of Science ®Google Scholar
• Tikoo, A., M. Varga, V. Ramesh, J. Gusella, and H. Maruta. 1994. An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J. Biol. Chem. 269:23387–23390.
   PubMed Web of Science ®Google Scholar
• Westwick, J. K., Q. T. Lambert, G. J. Clark, M. Symons, L. Van Aelst, R. G. Pestell, and C. J. Der. 1997. Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways. Mol. Cell. Biol. 17:1324–1335.
   PubMed Web of Science ®Google Scholar
• Xiao, G. H., A. Beeser, J. Chernoff, and J. R. Testa. 2002. p21-activated kinase links Rac/Cdc42 signaling to merlin. J. Biol. Chem. 277:883–886.
   PubMed Web of Science ®Google Scholar